Exact Sciences Corp
NASDAQ:EXAS

Watchlist Manager
Exact Sciences Corp Logo
Exact Sciences Corp
NASDAQ:EXAS
Watchlist
Price: 101.49 USD 0.24% Market Closed
Market Cap: 19.3B USD
Section:
 

Relative Value

The Relative Value of one EXAS stock under the Base Case scenario is 84.16 USD. Compared to the current market price of 101.49 USD, Exact Sciences Corp is Overvalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EXAS Relative Value
Base Case
84.16 USD
Overvaluation 17%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.2
P/S
P/S
Price to Sales
6.2
vs History
34
vs Industry
71
Median 3Y
4.4
Median 5Y
5.1
Industry
7.9
Forward
5.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-23.6
Median 5Y
-22.4
Industry
24
Forward
-140.9
More Details
49.7
P/OCF
P/OCF
Price to OCF
49.7
vs History
46
vs Industry
4
Median 3Y
49.5
Median 5Y
49.5
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
5
Median 3Y
44.1
Median 5Y
-17.4
Industry
23.7
More Details
7.7
P/B
P/B
Price to Book Value
7.7
vs History
7
vs Industry
27
Median 3Y
3.9
Median 5Y
4
Industry
3.4
More Details
6.7
EV/S
EV/S
Enterprise Value to Sales
6.7
vs History
34
vs Industry
58
Median 3Y
4.9
Median 5Y
5.7
Industry
8.3
Forward
6.2
More Details
9.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.9
vs History
34
vs Industry
56
Median 3Y
6.9
Median 5Y
7.7
Industry
10.3
More Details
324.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
324.9
vs History
15
vs Industry
0
Median 3Y
-19.1
Median 5Y
-25.6
Industry
6.7
Forward
44.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-58.4
Median 5Y
-52.3
Industry
7.2
Forward
-190
More Details
53.1
EV/OCF
EV/OCF
Enterprise Value to OCF
53.1
vs History
50
vs Industry
4
Median 3Y
54.9
Median 5Y
54.9
Industry
8.2
More Details
83.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
83.2
vs History
19
vs Industry
0
Median 3Y
-15.5
Median 5Y
-32.6
Industry
6.7
More Details
4.3
EV/IC
EV/IC
Enterprise Value to IC
4.3
vs History
11
vs Industry
46
Median 3Y
2.4
Median 5Y
2.5
Industry
5.7
More Details

Multiples Across Competitors

EXAS Competitors Multiples
Exact Sciences Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Exact Sciences Corp
NASDAQ:EXAS
19.2B USD 6.2 -19.5 324.9 -132.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 111 463.2 -162 126.7 -196 873.6 -194 627
US
Abbvie Inc
NYSE:ABBV
397B USD 6.7 169.1 16.4 23.2
US
Amgen Inc
NASDAQ:AMGN
170.3B USD 4.7 24.3 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
149.6B USD 5.1 18.4 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.4B USD 9.5 30.3 22.2 23.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.3 -527 -573.9 -558.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.5B USD 5.3 16.5 15.6 17.7
AU
CSL Ltd
ASX:CSL
87.9B AUD 3.8 19.5 13.1 16.3
NL
argenx SE
XBRU:ARGX
47B EUR 15.2 35.7 61.8 63.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54B USD 16.8 1 239.6 163 197.7
P/S Multiple
Revenue Growth P/S to Growth
US
Exact Sciences Corp
NASDAQ:EXAS
Average P/S: 3 101 236.5
6.2
15%
0.4
FR
Pharnext SCA
OTC:PNEXF
34 111 463.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
10%
0.9
US
E
Epizyme Inc
F:EPE
2 065.3
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.2
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.8
46%
0.4
P/E Multiple
Earnings Growth PEG
US
Exact Sciences Corp
NASDAQ:EXAS
Average P/E: 194.2
Negative Multiple: -19.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 126.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
169.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.3
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
9%
1.8
AU
CSL Ltd
ASX:CSL
19.5
11%
1.8
NL
argenx SE
XBRU:ARGX
35.7
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 239.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Exact Sciences Corp
NASDAQ:EXAS
Average EV/EBITDA: 71.9
324.9
185%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 873.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.6
11%
1.4
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
NL
argenx SE
XBRU:ARGX
61.8
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Exact Sciences Corp
NASDAQ:EXAS
Average EV/EBIT: 46.5
Negative Multiple: -132.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 627 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
13%
1.4
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
NL
argenx SE
XBRU:ARGX
63.5
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197.7
N/A N/A

See Also

Summary
EXAS intrinsic value, competitors valuation, and company profile.
DCF Valuation
EXAS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EXAS stock valuation using valuation multiples.
Wall Street Estimates
EXAS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EXAS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.